(Q45874963)

17 December 2017

title

European principles of haemophilia care (English)

1 reference

17 December 2017

0 references

B T Colvin

1

1 reference

17 December 2017

J Astermark

2

1 reference

17 December 2017

K Fischer

3

1 reference

17 December 2017

A Gringeri

4

1 reference

17 December 2017

R Lassila

5

1 reference

17 December 2017

W Schramm

6

1 reference

17 December 2017

A Thomas

7

1 reference

17 December 2017

J Ingerslev

8

1 reference

17 December 2017

Inter Disciplinary Working Group

9

1 reference

17 December 2017

publication date

30 January 2008

1 reference

17 December 2017

published in

Haemophilia

1 reference

17 December 2017

volume

14

1 reference

17 December 2017

issue

2

1 reference

17 December 2017

page(s)

361-374

1 reference

17 December 2017

Life expectancy in hemophilia outcome

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Establishing haemophilia care in developing countries: using data to overcome the barrier of pessimism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

A model for a regional system of care to promote the health and well-being of people with rare chronic genetic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Optimal haemophilia care versus the reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Haemophilia care in the developing world: benchmarking for excellence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Treatment of haemophilia in the developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Comprehensive care for haemophilia around the world

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Protecting and using patient information: the role of the Caldicott Guardian.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Supervised patient-management of hemophilia. A study of 45 patients with hemophilia A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Home treatment for patients with haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Delivery of health care in hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Handheld computers and paper diaries for documenting the use of factor concentrates used in haemophilia home therapy: a qualitative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Haemophilia prophylaxis in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Definitions for haemophilia prophylaxis and its outcomes: the Canadian consensus study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Prophylactic treatment effects on inhibitor risk: experience in one centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Prophylaxis for severe haemophilia: clinical and economical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

The emerging needs of persons living with haemophilia and HIV/AIDS in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Intracranial haemorrhages in French haemophilia patients (1991-2001): clinical presentation, management and prognosis factors for death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Experience with the hemophiliac child in a pediatric emergency department.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Presentation of severe haemophilia--a role for accident and emergency doctors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Emergency department use among Michigan children with special health care needs: an introductory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

The epidemiology of inhibitors in haemophilia A: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

The promise and challenges of bioengineered recombinant clotting factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Cellular and genetic therapies for haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

Future aspects of hemophilia research and care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01625.X

10.1111/J.1365-2516.2007.01625.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017